Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study

COVID-19 大流行对结直肠癌诊断、肿瘤特征和生存结局的影响:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: The coronavirus disease (COVID-19) pandemic has significantly disrupted healthcare systems, delaying the diagnosis and treatment of various diseases, including colorectal cancer (CRC). OBJECTIVES: To determine differences in patient demographics, clinical and histopathological characteristics, and survival rates in patients diagnosed with CRC before and during the first year of the pandemic. DESIGN: Retrospective cohort study. SETTING: Tertiary-care center. PATIENTS AND METHODS: We included 284 patients newly diagnosed with CRC, stratified into two cohorts: those diagnosed one year before and during the first year of the pandemic. Patient demographics, tumor characteristics (diameter, location, histological type, grade, multifocality, invasion depth, lymphovascular and perineural invasion, number of metastatic lymph nodes, tumor budding, and deposits), and clinical factors (operability, presence of distant metastases, and survival status) were evaluated. MAIN OUTCOME MEASURES: Tumor stage at diagnosis, histopathological aggressiveness, and overall survival rates. SAMPLE SIZE: 284 patients. RESULTS: Patients diagnosed during the pandemic had a significantly higher incidence of distant metastasis (14.8% vs. 5.1%, P=.005), a greater proportion of pT4b stage tumors (12.9% vs. 0.6%, P<.001), and a higher prevalence of rectosigmoid tumors (41.4% vs. 24.4%, P=.002). Additionally, tumor budding (63.6% vs. 47.3%, P=.014) and perineural invasion (35.2% vs. 24.5%, P=.053) were more common in the pandemic cohort. During the pandemic, significant shifts occurred in treatment modalities (P=.005), with increased utilization of neoadjuvant chemotherapy (18.8% vs. 11.5%), radiotherapy (22.7% vs. 12.2%), and palliative treatments (14.9% vs. 5.1%). Survival analysis showed no differences in survival rates between groups across all time points, including at three-year follow-up (P>.05). CONCLUSIONS: The COVID-19 pandemic has led to increased metastasis and advanced tumor rates in CRC cases, possibly owing to diagnostic delays. Although survival outcomes were similar between the periods, delayed effects on prognosis may manifest, necessitating long-term follow-up. LIMITATIONS: Retrospective design, single-center study.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。